🔎 Trials Near Me

Home › Kanser sa Respiratory Tract › Texas

Pag-aaral pangklinika para sa Kanser sa Respiratory Tract sa Texas

5 pag-aaral para sa Kanser sa Respiratory Tract ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • MD Anderson, Houston
  • NEXT Dallas, Irving
  • NEXT Oncology San Antonio, San Antonio
  • at 1 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Texas Oncology, Austin
  • William Beaumont Army Medical Center, Fort Bliss
  • Houston Methodist Hospital, Houston
  • at 3 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06119581

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • Texas Oncology, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07185997

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • UT Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update May 27, 2026 · NCT03093116

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 19, 2026 · NCT02984761

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.